Coronary Artery Plaque Buildup and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Research base: Moderate.
What is coronary artery plaque burden?
Coronary artery plaque burden refers to the total amount of atherosclerotic plaque present in the coronary arteries — the vessels that supply the heart muscle with oxygenated blood. Atherosclerosis is the process by which lipid-rich deposits accumulate within arterial walls, provoking inflammatory responses that lead to fibrosis, calcification, and progressive narrowing of the arterial lumen. Plaque burden is a measure of how far this process has progressed across the coronary tree at a given point in time.
Traditional GWAS of coronary artery disease (CAD) typically use clinical endpoints — myocardial infarction, revascularization, or clinical CAD events — as the trait of interest. Coronary artery plaque burden measured by imaging is a distinct and more direct phenotype: it captures the subclinical anatomical state of the coronary arteries rather than a downstream clinical consequence. Studying plaque burden directly may identify genetic variants that influence atherosclerosis biology more precisely than event-based endpoints, which are confounded by acute thrombosis, arrhythmia, and treatment effects.
The genetics behind coronary artery plaque burden
Because imaging-defined plaque burden requires specialized cardiovascular imaging (typically computed tomography angiography or coronary artery calcium scoring), large-scale GWAS of this phenotype have been limited by cohort size. The current dataset reflects a moderate-evidence study with 18 filtered candidate genes, drawn from the candidate regions associated with imaging-defined atherosclerosis.
Among the most biologically relevant genes in the filtered candidate set:
APOE (Apolipoprotein E) is the most extensively studied lipid metabolism gene in cardiovascular genetics. APOE encodes a major apolipoprotein involved in the transport and clearance of triglyceride-rich lipoproteins and LDL cholesterol by hepatic receptors. The three common APOE isoforms (ε2, ε3, ε4) have dramatically different effects on plasma lipid levels and atherosclerosis risk. The ε4 allele is associated with elevated LDL, reduced lipoprotein clearance, and increased atherosclerotic burden; the ε2 allele is generally protective for cardiovascular outcomes. APOE's presence in the plaque burden gene set is consistent with its established role in cholesterol delivery to the arterial wall.
ADAMTS7 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 7) is a zinc-dependent protease that has emerged as one of the most consistently replicated gene candidates in coronary artery disease GWAS across multiple independent studies. ADAMTS7 cleaves cartilage oligomeric matrix protein (COMP) in vascular smooth muscle cells, and this proteolytic activity is thought to promote smooth muscle cell migration into the arterial intima — a key step in plaque development. Loss-of-function ADAMTS7 variants are protective for CAD in human genetics studies, and ADAMTS7 inhibition reduces atherosclerosis in animal models, making this gene a validated biological target for plaque formation biology.
COL4A1 and COL4A2 (Collagen Type IV Alpha 1 and 2) encode the two major chains of type IV collagen, the primary structural component of basement membranes in the vascular wall. Variants in COL4A1 and COL4A2 have been associated with small vessel disease, intracranial aneurysm, and cerebrovascular conditions. In the coronary context, these genes likely influence the structural integrity of the arterial basement membrane that underlies endothelial function and vascular remodeling during plaque development.
HLA-DRA and HLA-DRB9, MHC class II genes, reflect the inflammatory and immunological component of atherosclerosis. Atherosclerotic plaques contain activated macrophages, T lymphocytes, and antigen-presenting cells that express MHC class II molecules. The inflammatory state of a plaque — particularly whether it is stable (fibrotic) or vulnerable (lipid-rich with thin fibrous cap) — is driven in part by this immune infiltrate. HLA associations in plaque burden may reflect variation in the inflammatory character of coronary atherosclerosis.
LEPR (Leptin Receptor) connects adipose tissue signaling to vascular biology. Leptin, the adipokine produced by fat tissue, signals through LEPR in multiple tissues including the vasculature and hypothalamus. Elevated leptin and leptin resistance, common in obesity, have been associated with endothelial dysfunction and pro-inflammatory vascular states. LEPR variants may influence the sensitivity of vascular cells to metabolic inflammatory signals that promote plaque accumulation.
What the research says
Gummesson et al. (2025) — Nature Communications — PMID 40164586
"A genome-wide association study of imaging-defined atherosclerosis." A 2025 genome-wide study using coronary imaging to directly phenotype atherosclerotic plaque burden, rather than relying on clinical cardiovascular event endpoints. This imaging-defined approach captures subclinical atherosclerosis and improves the precision of genetic association mapping by reducing phenotypic noise from acute thrombotic and arrhythmic events.
Research context: Coronary artery plaque burden GWAS is an emerging approach that complements traditional event-based CAD genetics. With 18 filtered candidate genes, the current evidence base is early-stage. Key genes like ADAMTS7 and APOE are among the strongest prior-evidence candidates for coronary atherosclerosis, lending biological credibility to the findings.
The moderate confidence tier reflects the single-study basis and the logistical challenges of phenotyping coronary plaque burden at GWAS scale. The identification of ADAMTS7 and APOE — both well-established in coronary artery disease genetics — provides reassuring convergent validity for the imaging-defined approach used in this study.
How coronary artery plaque burden affects you
Coronary artery plaque burden is a direct antecedent to major adverse cardiac events. Greater plaque burden increases the probability of acute plaque rupture (which can precipitate myocardial infarction), progressive luminal narrowing (causing stable angina and effort intolerance), and microvascular dysfunction. The degree of plaque burden is a strong predictor of future cardiovascular events even in asymptomatic individuals.
Genetic variants associated with higher plaque burden may reflect propensity toward more rapid lipid deposition, greater inflammatory activation within the vessel wall, impaired lesion resolution, or structural vulnerabilities in the arterial basement membrane. Understanding these genetic pathways can help contextualize why some individuals develop significant coronary atherosclerosis at younger ages or with lower traditional risk factor burden than expected.
Working with your variant profile
Genetic associations with coronary artery plaque burden reflect population-level GWAS signals from an imaging-based study. This data does not constitute a clinical evaluation of cardiovascular health, and individual risk for cardiovascular events depends on the full spectrum of modifiable and non-modifiable risk factors: blood pressure, lipid levels, smoking, diabetes, age, sex, and family history.
For individuals with concerns about coronary artery disease risk, clinical evaluation including lipid panels, blood pressure monitoring, and when indicated, coronary artery calcium scoring or CT angiography, is the standard pathway. Statin therapy, blood pressure management, and lifestyle modification have strong evidence bases for reducing atherosclerosis progression regardless of genetic background.
Related traits and genes
Coronary artery plaque burden is genetically related to coronary artery disease, LDL cholesterol levels, blood pressure, C-reactive protein, and carotid intima-media thickness. ADAMTS7 is one of the most replicated genes across CAD GWAS studies. APOE overlaps strongly with lipid trait genetics and Alzheimer's disease genetics (the ε4 allele is also the strongest common genetic risk factor for late-onset Alzheimer's). COL4A1/COL4A2 appear in small vessel disease and cerebrovascular genetics. HLA region variants overlap with other inflammatory and autoimmune conditions.
Frequently asked questions
What is ADAMTS7 and why is it linked to coronary plaque?
ADAMTS7 is a zinc metalloprotease that cleaves COMP (cartilage oligomeric matrix protein) in vascular smooth muscle cells. This proteolytic activity is thought to promote smooth muscle cell migration into the arterial intima — a key step in plaque formation. ADAMTS7 is one of the most consistently replicated gene candidates across coronary artery disease GWAS, and ADAMTS7 inhibition reduces atherosclerosis in animal models. Its presence in the imaging-defined plaque burden dataset is consistent with this established biology.
How does APOE affect coronary artery plaque?
APOE encodes apolipoprotein E, which directs the clearance of cholesterol-rich lipoproteins from the bloodstream via hepatic receptors. The ε4 isoform is less effective at clearing LDL and triglyceride-rich particles, leading to higher circulating lipid levels and greater cholesterol delivery to the arterial wall. Over time, elevated LDL exposure drives the lipid-accumulation phase of atherosclerosis. The ε2 isoform generally has the opposite effect, reducing LDL and conferring cardiovascular protection in most contexts.
How is coronary plaque burden measured in research?
Common imaging modalities include coronary computed tomography angiography (CCTA), which visualizes both calcified and non-calcified plaque segments, and coronary artery calcium (CAC) scoring, which quantifies the calcified component of plaque. Total plaque burden can be expressed as segment involvement score, total plaque volume, or calcium score depending on the method. The Gummesson et al. 2025 study used imaging-defined atherosclerosis as the GWAS phenotype, capturing plaque burden more directly than event-based outcomes.
Are the plaque burden genetics the same as coronary artery disease genetics?
Partially. Coronary artery plaque burden and CAD clinical events share many of the same upstream genetic factors (APOE, ADAMTS7, lipid pathway genes), but they are not identical phenotypes. CAD event GWAS capture the full sequence from atherosclerosis initiation through plaque rupture and thrombosis, while plaque burden GWAS capture only the anatomical stage. The imaging-defined approach may identify genes more specifically relevant to plaque accumulation and less affected by the acute event biology that confounds endpoint-based studies.
What role do the collagen genes COL4A1 and COL4A2 play in coronary plaque?
COL4A1 and COL4A2 encode the major chains of type IV collagen, the primary structural component of vascular basement membranes. Basement membrane integrity influences endothelial cell adhesion, smooth muscle cell function, and the mechanical properties of the vessel wall under hemodynamic stress. Variants in these genes have been associated with small vessel disease and cerebrovascular conditions; their presence in coronary plaque genetics may reflect how basement membrane vulnerability contributes to early atherosclerotic lesion formation and plaque instability.